Evaluation of Diabetes Care at Austrian GPs
Launched by ASTRAZENECA · Sep 17, 2009
Trial Information
Current as of August 02, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diabetes mellitus type II
- Exclusion Criteria:
- • Diabetes mellitus type I
- • Gestation diabetes
- • Induced diabetes
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Bernhard Ludvig
Study Chair
General Hospital Vienna
Guntram Schernthaner
Study Chair
Krankenanstalt Rudolfsstiftung
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials